Immunotherapy drug opens a new era of precision medicine for cancer – Los Angeles Times
Los Angeles Times |
Immunotherapy drug opens a new era of precision medicine for cancer
Los Angeles Times With little fanfare, the Food and Drug Administration did something this week that it's never done before: The agency approved a single prescription drug, pembrolizumab (marketed by Merck as Keytruda) for treatment of solid tumors in any organ so long … FDA approves cancer drug for personalized immunotherapy approach SAA Funding Contributes to FDA Approval Of Keytruda Expanded Keytruda Approval Signals New Phase for Precision Medicine, May Benefit NGS Panel Makers |
